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The activity of NF-kB/Rel nuclear factors is known to inhibit
apoptosis in various cell types. We investigated whether the
subtraction of NF-kB/Rel activity influenced the response of
11 AML (M1, M2 and M4) patients’ cells to AraC. To this
end we used a phosphorothioate double-stranded decoy oli-
godeoxynucleotide (ODN) carrying the NF-kB/Rel - consen-
sus sequence. Cell incubation with this ODN, but not its
mutated (scrambled) form used as a control, resulted in
abating the NF-kB/Rel nuclear levels in these cells, as veri-
fied by electrophoretic mobility shift assay (EMSA) of cells’
nuclear extracts. We incubated the leukemic cells with AraC
(32 or 1 mM), in either the absence or presence of the decoy
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The NF-kB/Rel transcription factors1 are dimers of pro-
teins (p50/p105 or NF-kB1, p52/p100 or NF-kB2, p65 or
RelA, c-Rel and RelB) containing an approximately 300
amino acid REL homology region. In cell cytoplasm, the
NF-kB/Rel complexes are retained by inhibitors of the
IkB (a-e) family; cytokines, hormones and other stimuli
can induce the phosphorylation and ubiquitin- mediated
degradation of the IkB proteins, allowing the NF-kB/Rel
dimers to reach the nucleus (reviewed in Ref. 1). In some
cell types, including B cells, thymocytes and neurons,
appreciable levels of NF-kB/Rel complexes can be
detected also in nuclei.1,2 Besides regulating a series of
genes involved in inflammatory processes or cell
adhesion,1,2 NF-kB/Rel activities (specifically, p65- or c-
Rel-containing dimers) can also inhibit apoptosis.3–13
Indeed, in a number of lines of different origins, cell
transfection with constructs expressing a ‘superrepressor’
IkBa (ie, mutated in the phosphorylation sites and hence
resistant to degradation),3–5 or the infection with a super-
repressor IkBa-carrying adenovirus,9,11 result in enhanc-
ing the apoptosis induced by TNF-a, ionizing radiations
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or the scrambled ODN, and analyzed cell apoptosis. The
spontaneous cell apoptosis detectable in the absence of
AraC (,25%) was not modulated by the oligonucleotide
presence in cell cultures. On the other hand, in 10 of the 11
samples tested, the decoy kB, but not the scrambled ODN
significantly (P , 0.01 in a Student’s t test) enhanced cell
apoptotic response to AraC. Such an effect was particularly
remarkable at low AraC doses (1 mM). These findings indi-
cate that NF-kB/Rel activity influences response to AraC in
human primary myeloblastic cells, and suggests that the
inhibition of NF-kB/Rel factors can improve the effect of
chemotherapy in AML. Gene Therapy (2000) 7, 1234–1237.
or chemotherapeutic agents. On the other hand, the over-
expression of p65 or c-Rel can protect the cells from
apoptosis.3,10 The inhibition of apoptosis appears to
involve more than one NF-kB/Rel-regulated gene,
including IAP caspase inhibitors,14,15 the Bcl2- homolog
Bfl-1/A112,13 and possibly others.8,16,17
The apoptosis-controlling activity of NF-kB/Rel factors
supports anti-tumor strategies based on inhibition of NF-
kB/Rel. Indeed, NF-kB/Rel inhibitors can be expected to
increase tumor cell sensitivity to apoptosis, leading to
enhanced effects of chemotherapeutic compounds.2,4,9,18–20
For the block of transcription factor activities, the recently
developed decoy strategy can represent a useful tool.21–25
In several cell types, the introduction of cis-element dou-
ble-stranded oligodeoxynucleotides (ODN) as decoy
results in attenuating the authentic interaction between
trans-factors and endogenous cis-elements, with sub-
sequent modulation of gene expression.21–26 By the effect
of decoy ODN, the nuclear levels of NF-kB/Rel transcrip-
tion factors can be downmodulated in primary cells26 and
the expression of NF-kB/Rel- inducible genes, such as
cytokines or cell surface molecules, is inhibited.7,24,27–29 To
analyze whether the inhibition of NF-kB/Rel factors can
influence leukemic cell response to pro-apoptotic chemo-
therapeutic agents, we investigated whether, in periph-
eral blood cells from acute myeloblastic leukemia (AML)
patients, NF-kB/Rel- specific decoy ODN modulated cell
Enhancement of AML cell apoptosis by NF-kB/Rel - decoy ODN
MF Romano et al
1235apoptosis induced by cytosine arabinoside (AraC). This
study was aimed at verifying the survival-regulating
property of NF-kB/Rel factors in human primary myelo-
blastic leukemia cells, and the effect of NF-kB/Rel decoy
ODN combined with a specific chemotherapeutic agent.
We analyzed the levels of NF-kB/Rel nuclear com-
plexes in peripheral blood leukemic cells obtained from
AML (M1, M2 and M4) patients. At variance to normal
human peripheral blood cells30 and CD34+ progenitors,26
in which NF-kB/Rel complexes are poorly detectable in
cell nuclei, we found the presence of NF-kB/Rel proteins
in cell nuclei in nine of nine AML samples tested. In cells
cultured with AraC, the NF-kB/Rel levels were not affec-
ted in five of the nine samples, and were only slightly
reduced in the remaining four samples (results not
shown). Representative results are shown in Figure 1. In
AML cells incubated with either medium alone or AraC,
Figure 1 Peripheral blood heparinized samples (.80% blasts) were
obtained from AML (M1, M2 and M4) patients before the start of therapy
and isolated by centrifugation through Ficoll–Hypaque (ICN Flow, Opera,
Italy) density gradient at 400 g for 30 min. Cells (106/ml) were incubated
in RPMI 1640 medium supplemented with 10% FCS, in the absence or
presence of cytosine arabinoside (AraC; Pharmacia & Upjohn, Puurs,
Belgium) (32 mm), and phosphorothioate oligodeoxynucleotides, corre-
sponding to the kB consensus sequence (5¢ -CCTTGAA
GGGATTTCCCTCC-3¢ )7 or its mutated (scrambled) form (5¢ -
CCTTGTACCATTGTTAGCC-3¢ ) (Primm Srl, Milan, Italy) (5 mm).
After 20 h, nuclear extracts were obtained.30 Nuclear proteins (3 mg) were
incubated with a 32P-labeled kB oligonucleotide (2 · 104 c.p.m.) at room
temperature for 20 min, in the presence of 1 mg poly(dI-dC), in 20 ml of
a buffer consisting of 10 mm Tris-HCl, pH 7.5, 50 mm NaCl, 1 mm
EDTA, 1 mm DTT and 5% glycerol. Where indicated, a 50· excess of a
competing unlabeled oligo (kB or NF-AT) was added in the incubation
mixture. Protein–DNA complexes were separated from free probe on a 6%
polyacrylamide gel, run in 0.25· Tris borate buffer at 200 V for 3 h at
room temperature.
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appreciable levels of DNA–protein complexes formed by
nuclear proteins with a 32P-labeled kB oligo were evident
in EMSA. Specifically, two bands (indicated by the
arrows) were detected, in analogy with patterns observed
in human peripheral blood T lymphocytes,30 and prob-
ably corresponding to p50/p65 (upper arrow) and
p50/p50 (lower arrow) dimers.1,30 These bands were
abolished when the nuclear proteins were incubated with
the 32P-labeled kB oligo in the presence of a 50 · excess
of a competing unlabeled kB oligo, and not of an unre-
lated (NF-AT) oligo. Therefore, they specifically corre-
sponded with the presence of NF-kB/Rel factors. When
AML cells were incubated with AraC in the presence of
an NF-kB/Rel- specific decoy phosphorothioate ODN,7
and then the nuclear extracts were obtained, the NF-
kB/Rel complexes were no longer detectable. Instead
they persisted in the extracts of AML cells incubated with
AraC in the presence of the scrambled oligo, used as con-
trol (Figure 1). Similar results were obtained by analyzing
three different AML cell preparations. We concluded that
cell incubation with the kB decoy oligo specifically
resulted in abating the NF-kB/Rel nuclear levels.
To investigate whether the subtraction of NF-kB/Rel
nuclear complexes affected cell response to AraC, we
incubated leukemic cells from 11 AML patients with the
chemotherapeutic agent, in either the absence or presence
of the decoy kB or the scrambled oligonucleotide, and
then analyzed cell apoptosis. The results are shown in
Figure 2. Cultures without AraC displayed ,25% of
apoptotic elements; the apoptosis percentages were not
significantly different in cultures with the decoy kB or
the scrambled oligonucleotide alone. On the other hand,
in 10 (patients 1, 2, 3, 4, 5, 6, 7, 9, 10, 11) of the 11 samples
tested, the presence of the decoy kB oligonucleotide
enhanced cell apoptotic response to AraC. In cultures
with 32 mm AraC (corresponding to a therapeutic dose of
about 385 mg per application), cell apoptosis in the 11
samples was significantly enhanced (P = 0.019) by the
decoy, but not the scrambled oligonucleotide. When
AraC was used at a lower dose (1 mm), the apoptotic
response was even more strikingly raised (P = 0.007) by
the decoy oligo. Four of the 11 samples tested with AraC
32 mm (samples 5, 8, 9, 11) did not show any significant
increase of their apoptotic response in the presence of the
kB decoy oligo. However, three of those four samples
(samples 5, 9, 11) did show a significant effect of the
decoy oligo at the lower AraC dose (1 mm) (Figure 2). In
five (patients 1, 5, 9, 10, 11) of the seven samples tested
with both doses of AraC, apoptosis was raised to a level
higher than that observed with 32 mm AraC alone.
Therefore, NF-kB/Rel- specific decoy, but not
scrambled ODN abated the nuclear levels of NF-kB/Rel
factors and enhanced AraC induced apoptosis of AML
cells. The lack of induction of AML cell death by NF-
kB/Rel inhibition, in the absence of apoptosis-triggering
agents, is consistent with findings concerning other cell
types, either normal26 or neoplastic.7,9,25 These results
concur in indicating that NF-kB/Rel activity is not
required for maintaining basal cell survival. Instead, NF-
kB/Rel factors can induce the expression of gene(s)
whose products inhibit apoptotic events (caspase inhibi-
tors, Bcl-2 homologs, etc).8,12–17 In this respect, the consti-
tutive nuclear NF-kB/Rel activities in some neoplastic
cells,31,32 including AML blasts, could represent one of
the factors contributing to the transformed state, by
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Figure 2 AML cells (106/ml) were incubated in RPMI 1640 medium sup-
plemented with 10% FCS, in the absence or presence of AraC and the kB
decoy or scrambled oligonucleotide (5 mm). After 3 days, cell apoptosis
was analyzed by propidium iodide incorporation and flow cytometry as
described.35 The P values were calculated using a Student’s paired t test,
GB-Stat 5.0 for Macintosh (Dynamic Microsystem, Silver Spring, MD,
USA).
contrasting apoptogenic stimuli – such as those delivered
by the immune system. Furthermore, NF-kB/Rel factors
can be responsible for reducing cell responsiveness to
cytotoxic agents. In fact, the inhibition of NF-kB/Rel
enhanced AML cell response to AraC, and particularly
amplified the effect of suboptimal doses of the drug.
These findings support the possibility, suggested for dif-
ferent types of tumors,9 that inhibitors of NF-kB/Rel
activity can enhance leukemic cell sensitivity to chemo-
therapy.
The decoy ODN can represent a useful tool for mani-
pulating the levels of NF-kB/Rel in primary cells. They
are more specific than proteasome inhibitors or nuclear
localization signals (NLS)-carrying peptides, have a bio-
logical effect in vivo24,25,29 and their active concentration
is comparable with that used for the systemic injection of
other phosphorothioate oligonucleotides in phase I
trials.33,34 Furthermore, since the NF-kB/Rel activity is
not apparently indispensable for the survival of normal
cells, including human primary CD34+ hematopoietic
progenitors,26 NF-kB/Rel- specific inhibitors, such as
ODN, could be particularly useful for improving bone
marrow purging strategies ex vivo and supporting in vivo
antineoplastic programs.
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